Publications by authors named "Craig Balog"

Claim this Profile
S
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Steven E Nissen, Kathy Wolski, Craig Balog, Daniel I Swerdlow, Alison C Scrimgeour

JAMA· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques.
Yu Kataoka, Kathy Wolski, Craig Balog, Kiyoko Uno, Rishi Puri

Eur Heart J Cardiovasc Imaging· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials.
Ozgur Bayturan, E Murat Tuzcu, Stephen J Nicholls, Craig Balog, Andrea Lavoie

JACC Cardiovasc Interv· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.
Ilke Sipahi, E Murat Tuzcu, Katherine E Wolski, Stephen J Nicholls, Paul Schoenhagen, Craig Balog

Ann Intern Med· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.
Ilke Sipahi, E Murat Tuzcu, Paul Schoenhagen, Katherine E Wolski, Stephen J Nicholls, Craig Balog

J Am Coll Cardiol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.
James C Blankenship, Craig Balog, Shelly K Sapp, Robert M Califf, A Michael Lincoff

Catheter Cardiovasc Interv· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
M Ashequl Islam, James C Blankenship, Craig Balog, Elias A Iliadis, A Michael Lincoff

Am J Cardiol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
Wojciech Mazur, Grzegorz L Kaluza, Shelly Sapp, Craig Balog, Eric J Topol

Am Heart J· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis